Tecovirimat is a key component of the global response to the mpox outbreak.
    Information on mpox is available here.

SIGA is monitoring the DRC mpox outbreak
For information on mpox in the Democratic Republic of the Congo, see here.

Tecovirimat-SIGA is approved by EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus.

Health Security

We are focused on providing preparedness solutions for unmet needs in biodefense.

For general inquiries, please visit our contact page. For mpox inquiries, please contact us at mpox@siga.com
(Note: Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus; TPOXX is approved by the U.S. FDA and Health Canada for the treatment of smallpox. TPOXX, Tecovirimat-SIGA is not approved as a treatment for mpox outside of the EU and UK.)

Our Pipeline

Attractive product and market expansion opportunities

Our Team

Experienced team of scientists and business leaders

Our Partners

Rich history of successful partnerships to support our vision

SIGA Technologies Receives Approval from UK for Tecovirimat

Learn More

News & Press Releases

More News

Health Security is a $15.2 billion market

Medical countermeasures for biological, chemical, radiological and nuclear attacks, as well as vaccines, therapeutics and diagnostics for emerging infectious diseases

  • Corporate Headquarters
    31 East 62nd Street
    New York, NY 10065
    (212) 672-9100

  • SIGA Development Operations
    4575 SW Research Way, Suite 110
    Corvallis, OR 97333
    (541) 753-2000

HCP and Product Inquiries: Call 541-766-3744

© 2024 SIGA Technologies, All Rights Reserved